Evidence map›Paper›PMID 42711341›Full record

ArticleNature communications2026

From helices to superhelices through hierarchical assembly across competing pathways.

Kyeong-Im Hong, Jorge S Valera, Ana M Garcia, Thomas M Hermans, Amparo Ruiz-Carretero

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kyeong-Im Hong *Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Científicas CSIC, Madrid, Spain.
Jorge S Valera *IMDEA Nanociencia, Madrid, Spain.ORCID http://orcid.org/0000-0001-8229-3107
Ana M GarciaUniversity of Strasbourg, Institute Charles Sadron, CNRS, UPR22, Strasbourg, France.
Thomas M HermansIMDEA Nanociencia, Madrid, Spain. thomas.hermans@imdea.org.ORCID http://orcid.org/0000-0003-1121-1754
Amparo Ruiz-CarreteroInstituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Científicas CSIC, Madrid, Spain. amparo.ruiz@csic.es.ORCID http://orcid.org/0000-0002-7336-2868

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding how molecular chirality propagates through competing self-assembly pathways remains a central challenge in supramolecular chemistry. We report a chiral π-conjugated quinquethiophene-rhodanine derivative forming four distinct and isolatable supramolecular aggregates from a single enantiomer under identical chemical conditions. These assemblies exhibit different chiroptical signatures, morphologies, hierarchical organization, and are selectively accessed through thermal and mechanical treatment. Calorimetry enables the experimental construction of the energy landscape, while long-term kinetic studies and spectral deconvolution reveal interconversions between helical structures, identifying an off-pathway hierarchical state. Remarkably, the most stable structure forms through a helix-to-superhelix transition governed by secondary nucleation. Cross-seeding experiments demonstrate that different dimensionality assemblies accelerate transformations across hierarchical levels, revealing an unusually interconnected assembly network. These results provide an experimental example where multiple supramolecular structures, their thermodynamic ordering, and kinetic connectivity are established within a single molecular system, showing how pathway selection programs chirality, hierarchy, and morphology in supramolecular materials.

Identifiers

PMID42711341
PMCPMC13554182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.